Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

  1. News
  2. Press Release

HITGEN and TAKEDA Enter DNA-Encoded Library Based Drug Discovery Research Collaboration Release Time:2017-09-11

Chengdu, China,Sep. 11th, 2017, HitGen Ltd announced that the company has entered into a research collaboration with Takeda Pharmaceutical Company Limited to discover novel small molecule leads for multiple targets in Takeda’s therapeutic areas of interest. According to the agreement, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads which will be licensed exclusively to Takeda. Under the terms of the agreement, HitGen will receive upfront compensation, and be eligible for milestone payments from Takeda. Specific financial details were not disclosed.


 “We are very pleased to enter this collaboration with Takeda, Japan’s largest pharmaceutical company. This world-wide collaboration further underscores the growing recognition and impact of DNA-encoded libraries for innovative drug discovery research. It also confirms the role of HitGen in this rapidly developing field. We will work closely with Takeda scientists to generate new lead compounds for their research programmes to address unmet medical needs.” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen. 


 ENDS 


About HitGen Ltd 


HitGen is a biotech company with headquarters and main research facilities based in Chengdu, China and with laboratory in USA. HitGen has established a unique platform for drug discovery research centred around DNA encoded chemical libraries (DELs). HitGen’s DELs contain more than 90 billion novel, diverse, drug-like small molecule and macrocycle compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed with tractable chemistry and proven results for finding drug leads against biological targets from known and novel classes. HitGen is working with multiple pharmaceutical, biotech companies and research institutes to discover and develop novel therapeutics of the future. 


For further information, please contact 


Dr. Jin Li, Chairman & CEO, HitGen Ltd. Tel: +86 28 85197385 (EXT. 8001) 

Dr. Barry Morgan, Chief Scientific Officer,HitGen Ltd. Tel: +1 5088409646


Questions?

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information